Investigational drug · Phase 2
RSS0343
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "RSS0343"
First trial start
2026
Mar 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSS0343", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "RSS0343" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Reistone Biopharma Company LimitedIndustry
NCT07349524 · 300 participants (planned) · Start Mar 10, 2026 · Primary completion Mar 2028
Drug: RSS0343 tablets; RSS0343 tablets Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06775340 · 252 participants (planned) · Start Jan 22, 2025 · Primary completion Nov 2027
Drug: RSS0343 Tabella · For: Adolescent Asthma
Sites: Guangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07101965 · 72 participants · Start Apr 7, 2024 · Primary completion Nov 6, 2024
Drug: RSS0343 tablets ;placebo; RSS0343 tablets ;placebo · For: Health Volunteer
Sites: Shandong, China
Reistone Biopharma Company LimitedIndustry
NCT07289464 · 48 participants · Start Jan 8, 2026 · Primary completion Aug 10, 2026
Drug: RSS0343 Tablets; RSS0343 Tablets Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Wuhan, China
Reistone Biopharma Company LimitedIndustry
NCT07696091 · 40 participants (planned) · Start Jul 2026 · Primary completion Sep 2026
Drug: RSS0343 Tablet; Rifampicin Capsules; RSS0343 Tablet; Clarithromycin Tablets · For: Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China
- A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal ImpairmentNot yet recruiting
Reistone Biopharma Company LimitedIndustry
NCT07940829 · 24 participants (planned) · Start Nov 2026 · Primary completion Feb 2027
Drug: RSS0343 Tablet · For: Non-cystic Fibrosis Bronchiectasis; Chronic Sinusitis Without Nasal Polyps; Chronic Obstructive Pulmonary Disease
Sites: Zhengzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.